OraSure Technologies, Inc. (OSUR)
Market Cap | 290.17M |
Revenue (ttm) | 224.26M |
Net Income (ttm) | 11.37M |
Shares Out | 74.59M |
EPS (ttm) | 0.15 |
PE Ratio | 25.75 |
Forward PE | 65.92 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 938,014 |
Open | 3.950 |
Previous Close | 3.920 |
Day's Range | 3.825 - 3.975 |
52-Week Range | 3.520 - 8.040 |
Beta | 0.05 |
Analysts | Hold |
Price Target | 5.50 (+41.39%) |
Earnings Date | Feb 25, 2025 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection d... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for OSUR stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 41.39% from the latest price.
News
NOWDiagnostics Responds with Countersuit Against Frivolous OraSure Claims
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, filed a claim on Jan. 13 against OraSure Techno...
OraSure to Present at the J.P Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that m...
CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence ...
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 ...
OraSure Technologies Acquires Sherlock Biosciences
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announce...
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no lo...
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that i...
OraSure to Participate in Upcoming Investor Conference
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Reports Q3 '24 Revenue of $39.9 Million
Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into bloo...
OraSure: An NCAV Diamond In The COVID Rough
OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net cu...
OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th
BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain...
Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc
On September 30, 2024, Neuberger Berman Group LLC, a prominent investment firm, made a significant addition to its investment portfolio by acquiring 3,927,692 shares of OraSure Technologies Inc (OSUR,...
OraSure Technologies Elects Jack Kenny to the Board of Directors
BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the el...
OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript
OraSure Technologies Inc (NASDAQ:OSUR) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - Presid...
OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th
BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certai...
OraSure Technologies Supports National HIV Testing Day
BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its sup...
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certai...
NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced ...
OraSure Technologies, Inc. (OSUR) Q4 2023 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q4 2023 Earnings Call Transcript
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
Q4 GAAP EPS of $0.27 ; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 E nters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics D...
OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th
BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certai...
OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company
The relationship expands OraSure's innovation pipeline with access to a broad portfolio of key Sapphiros products in development.
OraSure to Participate in Upcoming Investor Conferences
BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory...
OraSure Technologies, Inc. (OSUR) Q3 2023 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - P...